RESUMEN
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.
Asunto(s)
Alucinógenos , Dietilamida del Ácido Lisérgico , Psilocibina , Alucinógenos/farmacocinética , Alucinógenos/farmacología , Humanos , Psilocibina/farmacocinética , Psilocibina/farmacología , Dietilamida del Ácido Lisérgico/farmacología , Dietilamida del Ácido Lisérgico/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Agonistas del Receptor de Serotonina 5-HT2/farmacocinéticaRESUMEN
Lorcaserin, a selective serotonin 5-HT2C receptor agonist, was developed as an appetite suppressant with the rationale of minimizing the risk of cardiovascular toxicity associated with non-selective serotoninergic agents such as fenfluramine. Eight years after FDA approval, however, it was withdrawn from the market, when a large safety study suggested a potential cancer risk. Following in the fenfluramine footsteps and utilizing the repurposing approach coupled with the regulatory orphan drug designation, lorcaserin is currently in clinical development for the treatment of epilepsy. This potential novel indication builds on the evidence that 5-HT2C receptor stimulation can protect against seizures, and accounts at least in part for fenfluramine's antiseizure effects in Dravet syndrome models. In animal models, lorcaserin shows a narrower range of antiseizure activity than fenfluramine. In particular, lorcaserin is inactive in classical acute seizure tests such as maximal electroshock and subcutaneous pentylenetetrazole in mice and rats, and the 6-Hz stimulation model in mice. However, it is active in the GAERS absence seizure model, and in mutant zebrafish models of Dravet syndrome. Preliminary uncontrolled studies in patients with Dravet syndrome have yielded promising results, and a phase III, double-blind, placebo-controlled, parallel group trial is currently ongoing to assess its efficacy and safety in children and adults with Dravet syndrome.
Asunto(s)
Benzazepinas , Desarrollo de Medicamentos/métodos , Epilepsias Mioclónicas/tratamiento farmacológico , Animales , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/uso terapéutico , Benzazepinas/farmacocinética , Benzazepinas/uso terapéutico , Modelos Animales de Enfermedad , Humanos , Medición de Riesgo , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/uso terapéuticoRESUMEN
Alcohol use disorder (AUD) and methamphetamine use disorder (MUD) are prevalent and have high adverse impacts on both the individual and society. Current treatment strategies for these disorders are ineffective at a population level. Lorcaserin, a 5-HT2C receptor agonist, has shown potential at reducing the symptoms of substance use disorder. This pilot study (initiated prior to market withdrawal) examined feasibility and safety of lorcaserin treatment in people undergoing residential detoxification and treatment for AUD and MUD. This was an open label pilot study of lorcaserin where participants (n = 10 AUD; n = 8 MUD) received 10-mg lorcaserin daily for 4 days then twice daily for 1 month. Primary outcome measures included recruitment and retention rate, incidence of treatment-emergent events, incidence of methamphetamine or alcohol withdrawal-related events, heart rate, and blood pressure. Secondary measures included pharmacokinetic data and self-reported alcohol or methamphetamine use, craving, and psychological distress. AUD participants were recruited faster and had a greater retention rate compared with MUD participants. Lorcaserin did not alter vital signs, was well tolerated, and had a similar pharmacokinetic profile to individuals with obesity. Lorcaserin reduced self-reported alcohol and amphetamine-type substance use and craving in AUD and MUD participants, respectively. Self-reported psychological health also improved over the treatment period for all participants. Despite the pilot nature of this study, our data support the notion of 5-HT2C receptors as a therapeutic target for drug and alcohol abuse.
Asunto(s)
Consumo de Bebidas Alcohólicas , Benzazepinas/uso terapéutico , Metanfetamina , Receptor de Serotonina 5-HT2C , Agonistas del Receptor de Serotonina 5-HT2/uso terapéutico , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Adulto , Alcohólicos , Fármacos Antiobesidad/sangre , Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/uso terapéutico , Benzazepinas/farmacocinética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Obesidad/sangre , Proyectos Piloto , Agonistas del Receptor de Serotonina 5-HT2/sangre , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Síndrome de Abstinencia a Sustancias , Trastornos Relacionados con Sustancias/sangreRESUMEN
PURPOSE: The study demonstrates the use of Desorption Electrospray Ionization mass spectrometry imaging (DESI-MSI) for imaging of the PET tracer compound Cimbi-36 in brain tissue and compares imaging by DESI-MSI to imaging by autoradiography and PET. PROCEDURES: Rats were dosed intraperitoneally with 3 mg/kg of Cimbi-36 and euthanized at t = 5, 10, 15, 30, 60 and 120 min post-injection. The brains were removed, frozen and sectioned, and sagittal sections were imaged by DESI-MSI in positive ion mode. Additionally, brain sections from a non-dosed animal were incubated with 14C-labelled Cimbi-36 and imaged by autoradiography. Finally, PET images were acquired from an animal dosed with 11C-labelled Cimbi-36. RESULTS: DESI-MSI and autoradiography images of a sagittal brain sections showed similar distributions of Cimbi-36, with increased abundance in the frontal cortex and choroid plexus, regions which are high in 5-HT2A and 5-HT2C receptors. The PET image also showed increased abundance in cortex, but the spatial resolution was clearly inferior to DESI-MSI and autoradiography. The DESI-MSI results showed increased abundance of Cimbi-36 in brain tissue until 15 min, after which the abundance was declining. The PET-tracer was still clearly detectable at t = 120 min. Similar imaging of the kidneys showed the abundance of Cimbi-36 peaking at 30 min. Cimbi-36 was quantified in a t = 15 min brain section by quantitative DESI-MSI, resulting in tissue concentrations of 19.8 µg/g in cortex, 15.4 µg/g in cerebellum and 12.5 µg/g in whole brain. CONCLUSIONS: DESI imaging from an in vivo dosing experiment showed distribution of the PET tracer remarkably similar to what was obtained by autoradiography of an in vitro incubation experiment, indicating that the obtained results represent actual binding to certain receptors in the brain. DESI-MSI is suggested as a cost-effective screening tool, which does not rely on labelling of compounds.
Asunto(s)
Bencilaminas , Imagen Molecular/métodos , Fenetilaminas , Agonistas del Receptor de Serotonina 5-HT2 , Espectrometría de Masa por Ionización de Electrospray/métodos , Animales , Autorradiografía , Bencilaminas/química , Bencilaminas/farmacocinética , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Femenino , Fenetilaminas/química , Fenetilaminas/farmacocinética , Tomografía de Emisión de Positrones , Ratas Long-Evans , Agonistas del Receptor de Serotonina 5-HT2/química , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Distribución TisularRESUMEN
Serotonin plays a pivotal role in the initiation and modulation of locomotor behavior in the intact animal, as well as following spinal cord injury. Quipazine, a serotonin 2 receptor agonist, has been used successfully to initiate and restore motor behavior in rodents. Although evidence suggests that the effects of quipazine are spinally mediated, it is unclear whether intrathecal (IT) quipazine administration alone is enough to activate locomotor-like activity or whether additional stimulation is needed. Thus, the current study examined the effects of IT administration of quipazine in postnatal day 1 rats in two separate experiments. In experiment 1, quipazine (0.1, 0.3, or 1.0 mg/kg) was dissolved in saline and administered via IT injection to the thoracolumbar cord. There was no significant effect of drug on hindlimb alternating stepping. In experiment 2, quipazine (0.3 or 1.0 mg/kg) was dissolved in a polysorbate 80-saline solution (Tween 80) and administered via IT injection. Polysorbate 80 was used to disrupt the blood-brain barrier to facilitate absorption of quipazine. The injection was followed by tail pinch 5 minutes post-injection. A significant increase in the percentage of hindlimb alternating steps was found in subjects treated with 0.3 mg/kg quipazine, suggesting that IT quipazine when combined with sensory stimulation to the spinal cord, facilitates locomotor-like behavior. These findings indicate that dissolving the drug in polysorbate 80 rather than saline may heighten the effects of IT quipazine. Collectively, this study provides clarification on the role of quipazine in evoking spinally-mediated locomotor behavior.
Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Inyecciones Espinales/métodos , Cinesis , Actividad Motora/efectos de los fármacos , Polisorbatos/farmacología , Quipazina , Animales , Animales Recién Nacidos , Disponibilidad Biológica , Cinesis/efectos de los fármacos , Cinesis/fisiología , Quipazina/administración & dosificación , Quipazina/farmacocinética , Ratas , Receptores de Serotonina 5-HT2/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Solventes/farmacología , Traumatismos de la Médula Espinal/fisiopatologíaRESUMEN
BACKGROUND: Psilocybin is a serotonergic psychedelic with psychoactive effects mediated by serotonin 2A receptor (5-HT2AR) activation. It produces an acute psychedelic altered state of consciousness with a unique phenomenology that can be temporally characterized by three intensity phases: onset of psychoactive effect, a peak plateau and return to normal consciousness. AIMS: We evaluated whether pre-drug brain 5-HT2AR binding predicted the three phases of psilocybin subjective drug intensity (SDI) and retrospective self-report of mystical type experiences in healthy individuals. METHOD: Sixteen participants completed a pre-drug [11C]Cimbi-36 positron emission tomography scan to assess 5-HT2AR binding. On a separate day, participants completed a single psilocybin session (oral dose range 0.2-0.3 mg/kg), during which SDI was assessed every 20 min. The Mystical Experience Questionnaire (MEQ) was completed at the end of the session. The three SDI phases were modelled using segmented linear regressions. We evaluated the associations between neocortex 5-HT2AR binding and SDI/MEQ outcomes using linear regression models. RESULTS: Neocortex 5-HT2AR was statistically significantly negatively associated with peak plateau duration and positively with time to return to normal waking consciousness. It was also statistically significantly negatively associated with MEQ total score. CONCLUSION: This is the first study to investigate how individual brain 5-HT2AR binding predicts subjective effects of a single dose of psilocybin. Our findings reinforce the role of cerebral 5-HT2AR in shaping the temporal and mystical features of the psychedelic experience. Future studies should examine whether individual brain levels of 5-HT2AR have an impact on therapeutic outcomes in clinical studies.
Asunto(s)
Encéfalo , Misticismo/psicología , Psilocibina , Adulto , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Estado de Conciencia/efectos de los fármacos , Estado de Conciencia/fisiología , Femenino , Alucinógenos/administración & dosificación , Alucinógenos/farmacocinética , Humanos , Masculino , Evaluación de Resultado en la Atención de Salud , Tomografía de Emisión de Positrones/métodos , Psilocibina/administración & dosificación , Psilocibina/farmacocinética , Psicotrópicos/administración & dosificación , Psicotrópicos/farmacocinética , Receptores de Serotonina 5-HT2/metabolismo , Autoimagen , Agonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Agonistas del Receptor de Serotonina 5-HT2/farmacocinéticaRESUMEN
The serotonin 2A receptor (5-HT2AR) is implicated in the pathophysiology and treatment of various psychiatric disorders. [18 F]altanserin and [11 C]Cimbi-36 positron emission tomography (PET) allow for high-resolution imaging of 5-HT2AR in the living human brain. Cerebral 5-HT2AR binding is strongly genetically determined, though the impact of specific variants is poorly understood. Candidate gene studies suggest that HTR2A single nucleotide polymorphisms including rs6311/rs6313, rs6314, and rs7997012 may influence risk for psychiatric disorders and mediate treatment response. Although known to impact in vitro expression of 5-HT2AR or other serotonin (5-HT) proteins, their effect on human in vivo brain 5-HT2AR binding has as of yet been insufficiently studied. We thus assessed the extent to which these variants and the commonly studied 5-HTTLPR predict neocortex in vivo 5-HT2AR binding in healthy adult humans. We used linear regression analyses and likelihood ratio tests in 197 subjects scanned with [18 F]altanserin or [11 C]Cimbi-36 PET. Although we observed genotype group differences in 5-HT2AR binding of up to ~10%, no genetic variants were statistically significantly predictive of 5-HT2AR binding in what is the largest human in vivo 5-HT2AR imaging genetics study to date. Thus, in vitro and post mortem results suggesting effects on 5-HT2AR expression did not carry over to the in vivo setting. To any extent these variants might affect clinical risk, our findings do not support that 5-HT2AR binding mediates such effects. Our observations indicate that these individual variants do not significantly contribute to genetic load on human in vivo 5-HT2AR binding.
Asunto(s)
Neocórtex/metabolismo , Receptor de Serotonina 5-HT2A/genética , Receptor de Serotonina 5-HT2A/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Bencilaminas/farmacocinética , Femenino , Radioisótopos de Flúor/farmacocinética , Humanos , Ketanserina/análogos & derivados , Ketanserina/farmacocinética , Masculino , Persona de Mediana Edad , Neocórtex/diagnóstico por imagen , Fenetilaminas/farmacocinética , Tomografía de Emisión de Positrones , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Antagonistas de la Serotonina/farmacocinética , Adulto JovenRESUMEN
Targeting the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such as obesity and substance use disorders. Expanding upon our recently described 5-HT2CR-positive allosteric modulators (PAMs) based on the 4-alkylpiperidine-2-carboxamide scaffold, we optimized the undecyl moiety at the 4-position with variations of cyclohexyl- or phenyl-containing fragments to reduce rotatable bonds and lipophilicity. Compound 12 (CTW0415) was discovered as a 5-HT2CR PAM with improved pharmacokinetics and reduced off-target interactions relative to our previous series of molecules. The in vivo efficacy of compound 12 to potentiate the effects of a selective 5-HT2CR agonist was established in a drug discrimination assay. Thus, 12 is reported as a 5-HT2CR PAM with characteristics suitable for in vivo pharmacological studies to further probe the biological and behavioral mechanisms of allosteric modulation of a receptor important in several chronic diseases.
Asunto(s)
Piperidinas/farmacología , Receptor de Serotonina 5-HT2C/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Animales , Sitios de Unión , Células CHO , Cricetulus , Diseño de Fármacos , Simulación del Acoplamiento Molecular , Estructura Molecular , Piperidinas/síntesis química , Piperidinas/metabolismo , Piperidinas/farmacocinética , Receptor de Serotonina 5-HT2C/química , Agonistas del Receptor de Serotonina 5-HT2/síntesis química , Agonistas del Receptor de Serotonina 5-HT2/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Relación Estructura-ActividadRESUMEN
A series of potential new 5-HT2 receptor scaffolds based on a simplification of the clinically studied, 5-HT2CR agonist vabicaserin, were designed. An in vivo feeding assay early in our screening process played an instrumental part in the lead identification process, leading us to focus on a 6,5,7-tricyclic scaffold. A subsequent early SAR investigation provided potent agonists of the 5-HT2C receptor that were highly selective in both functional and binding assays, had good rat PK properties and that significantly reduced acute food intake in the rat.
Asunto(s)
Benzodiazepinas/farmacología , Compuestos Heterocíclicos con 3 Anillos/farmacología , Receptor de Serotonina 5-HT2C/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Animales , Benzodiazepinas/síntesis química , Benzodiazepinas/metabolismo , Benzodiazepinas/farmacocinética , Perros , Descubrimiento de Drogas , Estabilidad de Medicamentos , Compuestos Heterocíclicos con 3 Anillos/síntesis química , Compuestos Heterocíclicos con 3 Anillos/metabolismo , Compuestos Heterocíclicos con 3 Anillos/farmacocinética , Humanos , Macaca fascicularis , Masculino , Ratones , Microsomas/metabolismo , Estructura Molecular , Ratas Sprague-Dawley , Agonistas del Receptor de Serotonina 5-HT2/síntesis química , Agonistas del Receptor de Serotonina 5-HT2/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Relación Estructura-ActividadRESUMEN
The selective 5-HT2C receptor agonist lorcaserin, in conjunction with lifestyle modification, was approved by the FDA in 2012 for weight management. It has been marketed in the US as Belviq® since 2013. This article provides a review of the preclinical and clinical pharmacology of lorcaserin, including its pharmacokinetic and safety profiles. Preclinical studies with lorcaserin initially focused on simple measures of food intake and body weight gain, but have now expanded to include studies on its effects on appetitive aspects of feeding behaviour and models of binge-eating. A significant number of studies have also shown that lorcaserin alters behaviours related to drug use and addiction, in rodents and non-human primates. Potential clinically-relevant effects of lorcaserin have also been reported in models of pain and seizure-like activity. Not surprisingly, the majority of clinical work with lorcaserin has focused on its effects on weight gain, and on physiological processes related to energy intake. However, results of clinical trials and experimental laboratory studies involving lorcaserin are now appearing which describe effects on a range of other behaviours and physiological functions. These include smoking cessation, cocaine self-administration, and behavioural and brain responses to food cues. All of this work suggests that lorcaserin may have therapeutic potential for a variety of disorders and conditions beyond obesity. Based on clinical experience, including the outcomes from several, large, well-powered clinical obesity trials at the approved 10mg BID dose both pre and post approval, a priori concerns about cardiac valvulopathy have largely been allayed. However, as with any recently approved first-in-class pharmacotherapy, there may be yet-unknown risks, as well as benefits, associated with use of lorcaserin. Nonetheless, the current safety profile and an expanding post approval safety data base should encourage further experimental laboratory-based and clinical trial-based research with lorcaserin in targeted populations to investigate its full therapeutic potential.
Asunto(s)
Fármacos Antiobesidad/farmacología , Benzazepinas/farmacología , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Animales , Fármacos Antiobesidad/efectos adversos , Fármacos Antiobesidad/farmacocinética , Conducta Adictiva/tratamiento farmacológico , Benzazepinas/efectos adversos , Benzazepinas/farmacocinética , Conducta Alimentaria/efectos de los fármacos , Humanos , Obesidad/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT2/efectos adversos , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Trastornos Relacionados con Sustancias/tratamiento farmacológicoRESUMEN
Schistosomiasis is a debilitating tropical disease caused by infection with parasitic blood flukes. Approximately 260 million people are infected worldwide, underscoring the clinical and socioeconomic impact of this chronic infection. Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mainstay for over three decades of clinical use. However, the molecular target(s) of PZQ remain undefined. Here we identify a molecular target for the antischistosomal eutomer - (R)-PZQ - which functions as a partial agonist of the human serotoninergic 5HT2B receptor. (R)-PZQ modulation of serotoninergic signaling occurs over a concentration range sufficient to regulate vascular tone of the mesenteric blood vessels where the adult parasites reside within their host. These data establish (R)-PZQ as a G-protein-coupled receptor ligand and suggest that the efficacy of this clinically important anthelmintic is supported by a broad, cross species polypharmacology with PZQ modulating signaling events in both host and parasite.
Asunto(s)
Antihelmínticos/metabolismo , Arterias Mesentéricas/efectos de los fármacos , Venas Mesentéricas/efectos de los fármacos , Praziquantel/metabolismo , Schistosoma mansoni/efectos de los fármacos , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Vasoconstricción/efectos de los fármacos , Animales , Antihelmínticos/farmacología , Línea Celular , Simulación por Computador , Agonismo Parcial de Drogas , Femenino , Humanos , Ratones , Miografía , Praziquantel/farmacología , Receptor de Serotonina 5-HT2B/efectos de los fármacos , Receptor de Serotonina 5-HT2B/metabolismo , Esquistosomiasis mansoni/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT2/farmacologíaRESUMEN
Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT2C receptor to identify atypical agonist structures. We additionally report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT2C. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT2C with high selectivity over the related 5-HT2A and 5-HT2B receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1H-pyrazol-5-yl)pyridazin-3-amine (69). Oral administration of 69 to rats reduced food intake in an ad libitum feeding model, which could be completely reversed by a selective 5-HT2C antagonist.
Asunto(s)
Arginina/análogos & derivados , Flavonas/química , Receptor de Serotonina 5-HT2C/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/química , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/genética , Animales , Arginina/síntesis química , Arginina/química , Arginina/farmacología , Encéfalo/metabolismo , Células CACO-2 , Permeabilidad de la Membrana Celular , Conducta Alimentaria/efectos de los fármacos , Flavonas/síntesis química , Flavonas/farmacología , Células HEK293 , Humanos , Masculino , Membranas Artificiales , Ratones Noqueados , Microsomas Hepáticos/metabolismo , Mutación , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2A/metabolismo , Receptor de Serotonina 5-HT2B/metabolismo , Receptor de Serotonina 5-HT2C/genética , Agonistas del Receptor de Serotonina 5-HT2/síntesis química , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Relación Estructura-ActividadRESUMEN
OBJECTIVE: The potent hallucinogenic drug 25I-NBOMe has recently emerged on the drug market. We present a case with analytically confirmed 25I-NBOMe intoxication from the prospective study "SPICE II Plus". CASE REPORT: Because of a severe headache a 42-year-old man took one sip of a pediatric analgesic syrup, which had been refilled with a self-made solution of 25I-NBOMe in ethanol. Thirty minutes later restlessness occurred. On arrival in the emergency department mydriasis, strong sweating, disorientation, and agitation were noticed. Within short time the patient developed severe agitation, coenesthesia, and complex hallucinations. In blood serum samples obtained at admission revealed the presence of 25I-NBOMe (34 ng/mL), 2C-I (12 ng/mL) and 25I-NBOH (<1 ng/mL) (LC-ESI-MS/MS). The presumed analgesic syrup contained 25I-NBOMe (2800 µg/mL), and besides ethanol no other compounds were detected. After six hours, the symptoms resolved without further complications. CONCLUSIONS: This is a unique case of an analytically confirmed, accidental ingestion of 25I-NBOMe in a drug naïve adult. The finding of 2C-I in the serum sample 50 minutes after intake indicates a fast metabolic breakdown of 25I-NBOMe due to first-pass metabolism.
Asunto(s)
Accidentes , Analgésicos/envenenamiento , Dimetoxifeniletilamina/análogos & derivados , Síndromes de Neurotoxicidad/etiología , Intoxicación/etiología , Agonistas del Receptor de Serotonina 5-HT2/envenenamiento , Adulto , Analgésicos/sangre , Analgésicos/farmacocinética , Cromatografía Liquida , Dimetoxifeniletilamina/sangre , Dimetoxifeniletilamina/farmacocinética , Dimetoxifeniletilamina/envenenamiento , Humanos , Masculino , Síndromes de Neurotoxicidad/diagnóstico , Síndromes de Neurotoxicidad/terapia , Intoxicación/diagnóstico , Intoxicación/terapia , Agonistas del Receptor de Serotonina 5-HT2/sangre , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masas en TándemRESUMEN
Drug-induced valvular heart disease (VHD) is a serious side effect linked to long-term treatment with 5-hydroxytryptamine (serotonin) receptor 2B (5-HT2B) agonists. Safety assessment for off-target pharmacodynamic activity is a common approach used to screen drugs for this undesired property. Such studies include in vitro assays to determine whether the drug is a 5-HT2B agonist, a necessary pharmacological property for development of VHD. Measures of in vitro binding affinity (IC50, Ki) or cellular functional activity (EC50) are often compared to maximum therapeutic free plasma drug levels ( fCmax) from which safety margins (SMs) can be derived. However, there is no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use. The strengths and limitations of SM determinations and current risk assessment methodology are reviewed and evaluated. It is concluded that the use of SMs based on Ki values, or those relative to serotonin (5-HT), appears to be a better predictor than the use of EC50 or EC50/human fCmax values for determining whether known 5-HT2B agonists have resulted in VHD. It is hoped that such a discussion will improve efforts to reduce this preventable serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.
Asunto(s)
Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Enfermedades de las Válvulas Cardíacas/inducido químicamente , Medición de Riesgo , Agonistas del Receptor de Serotonina 5-HT2/toxicidad , Animales , Línea Celular , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/normas , Regulación Gubernamental , Enfermedades de las Válvulas Cardíacas/metabolismo , Humanos , Técnicas In Vitro , Unión Proteica , Receptores de Serotonina 5-HT2/metabolismo , Medición de Riesgo/legislación & jurisprudencia , Medición de Riesgo/métodos , Agonistas del Receptor de Serotonina 5-HT2/farmacocinéticaRESUMEN
The toxic hallucinogen 25B-NBOMe is very rapidly degraded by human liver microsomes and has low oral bioavailability. Herein we report on the synthesis, microsomal stability, and 5-HT2A/5-HT2C receptor profile of novel analogues of 25B-NBOMe modified at the primary site of metabolism. Although microsomal stability could be increased while maintaining potent 5-HT2 receptor agonist properties, all analogues had an intrinsic clearance above 1.3 L/kg/h predictive of high first-pass metabolism.
Asunto(s)
Fenetilaminas/farmacología , Fenetilaminas/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Anisoles/química , Línea Celular , Evaluación Preclínica de Medicamentos , Estabilidad de Medicamentos , Células HEK293 , Alucinógenos/química , Humanos , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/metabolismo , Fenetilaminas/síntesis química , Fenetilaminas/química , Receptor de Serotonina 5-HT2A/genética , Receptor de Serotonina 5-HT2A/metabolismo , Receptor de Serotonina 5-HT2C/genética , Receptor de Serotonina 5-HT2C/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/síntesis química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with Parkinson's disease may develop Parkinson's disease psychosis, which is associated with increased morbidity and mortality and has few treatment options. This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis.
Asunto(s)
Antipsicóticos/uso terapéutico , Deluciones/tratamiento farmacológico , Alucinaciones/tratamiento farmacológico , Enfermedad de Parkinson/tratamiento farmacológico , Piperidinas/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT2/uso terapéutico , Urea/análogos & derivados , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Antipsicóticos/farmacocinética , Deluciones/metabolismo , Deluciones/psicología , Aprobación de Drogas , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Alucinaciones/metabolismo , Alucinaciones/psicología , Humanos , Estructura Molecular , Enfermedad de Parkinson/psicología , Piperidinas/administración & dosificación , Piperidinas/efectos adversos , Piperidinas/farmacocinética , Ensayos Clínicos Controlados Aleatorios como Asunto , Agonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Agonistas del Receptor de Serotonina 5-HT2/efectos adversos , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Resultado del Tratamiento , Urea/administración & dosificación , Urea/efectos adversos , Urea/farmacocinética , Urea/uso terapéuticoRESUMEN
INTRODUCTION: [(11)C]Cimbi-36 is a recently developed serotonin 2A (5-HT2A) receptor agonist positron emission tomography (PET) radioligand that has been successfully applied for human neuroimaging. Here, we investigate the test-retest variability of cerebral [(11)C]Cimbi-36 PET and compare [(11)C]Cimbi-36 and the 5-HT2A receptor antagonist [(18)F]altanserin. METHODS: Sixteen healthy volunteers (mean age 23.9 ± 6.4years, 6 males) were scanned twice with a high resolution research tomography PET scanner. All subjects were scanned after a bolus of [(11)C]Cimbi-36; eight were scanned twice to determine test-retest variability in [(11)C]Cimbi-36 binding measures, and another eight were scanned after a bolus plus constant infusion with [(18)F]altanserin. Regional differences in the brain distribution of [(11)C]Cimbi-36 and [(18)F]altanserin were assessed with a correlation of regional binding measures and with voxel-based analysis. RESULTS: Test-retest variability of [(11)C]Cimbi-36 non-displaceable binding potential (BPND) was consistently <5% in high-binding regions and lower for reference tissue models as compared to a 2-tissue compartment model. We found a highly significant correlation between regional BPNDs measured with [(11)C]Cimbi-36 and [(18)F]altanserin (mean Pearson's r: 0.95 ± 0.04) suggesting similar cortical binding of the radioligands. Relatively higher binding with [(11)C]Cimbi-36 as compared to [(18)F]altanserin was found in the choroid plexus and hippocampus in the human brain. CONCLUSIONS: Excellent test-retest reproducibility highlights the potential of [(11)C]Cimbi-36 for PET imaging of 5-HT2A receptor agonist binding in vivo. Our data suggest that Cimbi-36 and altanserin both bind to 5-HT2A receptors, but in regions with high 5-HT2C receptor density, choroid plexus and hippocampus, the [(11)C]Cimbi-36 binding likely represents binding to both 5-HT2A and 5-HT2C receptors.
Asunto(s)
Bencilaminas/farmacocinética , Encéfalo/metabolismo , Ketanserina/análogos & derivados , Fenetilaminas/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Antagonistas del Receptor de Serotonina 5-HT2/farmacocinética , Bencilaminas/metabolismo , Radioisótopos de Carbono/metabolismo , Radioisótopos de Carbono/farmacocinética , Femenino , Radioisótopos de Flúor/metabolismo , Radioisótopos de Flúor/farmacocinética , Humanos , Ketanserina/metabolismo , Ketanserina/farmacocinética , Masculino , Neuroimagen/métodos , Fenetilaminas/metabolismo , Tomografía de Emisión de Positrones/métodos , Radiofármacos/metabolismo , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Agonistas del Receptor de Serotonina 5-HT2/metabolismo , Antagonistas del Receptor de Serotonina 5-HT2/metabolismo , Adulto JovenRESUMEN
Xanthone derivatives have been shown to posses many biological properties. Some of them act within the central nervous system and show neuroprotective or antidepressant-like properties. Taking this into account we investigated antidepressant-like activity in mice and the possible mechanism of action of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one (HBK-11) - a new xanthone derivative. We demonstrated that HBK-11 produced antidepressant-like effects in the forced swim test and tail suspension test, comparable to that of venlafaxine. The combined treatment with sub-effective doses of HBK-11 and fluoxetine (but not reboxetine or bupropion) significantly reduced the immobility in the forced swim test. Moreover, the antidepressant-like activity of HBK-11 in the aforementioned test was blocked by p-chlorophenylalanine, and significantly reduced by serotonergic 5HT1A receptor antagonist - WAY-1006335 and 5HT2A/C receptor antagonist - ritanserin. As none of the above treatments influenced the spontaneous locomotor activity, it can be concluded that HBK-11 mediates its activity through a serotonergic system, and its antidepressant-like effect involves 5HT1A and 5HT2A/C receptor activation. Furthermore, at antidepressant-like doses HBK-11 did not cause the mice to display locomotor deficits in rotarod or chimney tests. Considering the pharmacokinetic profile, HBK-11 demonstrated rapid absorption after i.p. administration, high clearance value, short terminal half-life, very high volume of distribution and incomplete bioavailability. The compound studied had good penetration into the brain tissue of mice. Since studied xanthone derivative seems to present interesting, untypical mechanism of antidepressant-like action i.e. 5HT2A/C receptor activation, it may have a potential in the treatment of depressive disorders, and surely requires further studies.
Asunto(s)
Antidepresivos/farmacología , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Depresión/tratamiento farmacológico , Actividad Motora/efectos de los fármacos , Piperazinas/farmacología , Receptor de Serotonina 5-HT1A/efectos de los fármacos , Receptor de Serotonina 5-HT2A/efectos de los fármacos , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Agonistas del Receptor de Serotonina 5-HT1/farmacología , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Xantenos/farmacología , Xantonas/farmacología , Animales , Antidepresivos/farmacocinética , Encéfalo/metabolismo , Encéfalo/fisiopatología , Depresión/diagnóstico , Depresión/metabolismo , Depresión/fisiopatología , Depresión/psicología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Piperazinas/farmacocinética , Receptor de Serotonina 5-HT1A/metabolismo , Receptor de Serotonina 5-HT2A/metabolismo , Receptor de Serotonina 5-HT2C/metabolismo , Prueba de Desempeño de Rotación con Aceleración Constante , Agonistas del Receptor de Serotonina 5-HT1/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Natación , Xantenos/farmacocinética , Xantonas/farmacocinéticaRESUMEN
The central 5-hydroxytryptamine (5-HT; serotonin) system represents a fundamental component of the brain's control of energy homeostasis. Medications targeting the 5-HT pathway have been at the forefront of obesity treatment for the past 15 years. Pharmacological agents targeting 5-HT receptors (5-HTR), in combination with genetic models of 5-HTR manipulation, have uncovered a role for specific 5-HTRs in energy balance and reveal the 5-HT2 C R as the principal 5-HTR mediating this homeostatic process. Capitalising on this neurophysiological machinery, 5-HT2 C R agonists improve obesity and glycaemic control in patient populations. The underlying therapeutic mechanism has been probed using model systems and appears to be achieved primarily through 5-HT2 C R modulation of the brain melanocortin circuit via activation of pro-opiomelanocortin neurones signalling at melanocortin4 receptors. Thus, 5-HT2 C R agonists offer a means to improve obesity and type 2 diabetes, which are conditions that now represent global challenges to human health.
Asunto(s)
Obesidad/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT2/uso terapéutico , Apetito/efectos de los fármacos , Disponibilidad Biológica , Metabolismo Energético , Humanos , Proopiomelanocortina/fisiología , Serotonina/fisiología , Agonistas del Receptor de Serotonina 5-HT2/farmacocinética , Agonistas del Receptor de Serotonina 5-HT2/farmacologíaRESUMEN
RATIONALE: Synergistic or supra-additive interactions between the anorectics (dex)fenfluramine and phentermine have been reported previously in the rat and in the clinic. Studies with 5-HT2C antagonists and 5-HT2C knockouts have demonstrated dexfenfluramine hypophagia in the rodent to be mediated by actions at the 5-HT2C receptor. Given the recent FDA approval of the selective 5-HT2C agonist lorcaserin (BELVIQ®) for weight management, we investigated the interaction between phentermine and 5-HT2C agonists on food intake. OBJECTIVES: This study aims to confirm dexfenfluramine-phentermine (dex-phen) synergy in a rat food intake assay, to extend these findings to other 5-HT2C agonists, and to determine whether pharmacokinetic interactions could explain synergistic findings with particular drug combinations. METHODS: Isobolographic analyses were performed in which phentermine was paired with either dexfenfluramine, the 5-HT2C agonist AR630, or the 5-HT2C agonist lorcaserin, and inhibition of food intake measured in the rat. Subsequent studies assessed these same phentermine-drug pair combinations spanning both the full effect range and a range of fixed ratio drug combinations. Satellite groups received single doses of each drug either alone or in combination with phentermine, and free brain concentrations were measured. RESULTS: Dex-phen synergy was confirmed in the rat and extended to the 5-HT2C agonist AR630. In contrast, although some synergistic interactions between lorcaserin and phentermine were observed, these combinations were largely additive. Synergistic interactions between phentermine and dexfenfluramine or AR630 were accompanied by combination-induced increases in brain levels of phentermine. CONCLUSIONS: Dex-phen synergy in the rat is caused by a pharmacokinetic interaction, resulting in increased central concentrations of phentermine.